EW FY2025 Q3 IMPROVING

Edwards Lifesciences Corporation earnings call

Oct 30, 2025 · 13:00 ET Bernard ZavigianDevine ChopraMark Wilterding

Buzzberg read

Company raises full-year sales growth guidance to high end of 9-10%

Edwards Lifesciences reported strong Q3 FY2025 results with total revenue of $1.55B (+12.6% cc) and adj. EPS of $0.67, beating expectations. Management raised full-year TAVR and EPS guidance, citing renewed clinical focus, positive data from TCT (7-year PARTNER 3 and 10-year durability), and strong TMTT growth (Pascal, Evoque, M3). Guidance for Q4 implies a sequential dip but full-year raised. No specific cross-company mentions were made. Q3 total revenue $1.55B (+12.6% cc) beat expectations; TAVR $1.15B (+10.6% cc), TMTT $144M (+53%), Surgical $258M (+5.6%).

Buzzberg read Company raises full-year sales growth guidance to high end of 9-10% Edwards Lifesciences reported strong Q3 FY2025 results with total revenue of $1.55B (+12.6% cc) and adj. EPS of $0.67, beating expectations. Management raised full-year TAVR and EPS guidance, citing renewed clinical focus, positive data from TCT (7-year PARTNER 3 and 10-year durability), and strong TMTT growth (Pascal, Evoque, M3). Guidance for Q4 implies a sequential dip but full-year raised. No specific cross-company mentions were made. Q3 total revenue $1.55B (+12.6% cc) beat expectations; TAVR $1.15B (+10.6% cc), TMTT $144M (+53%), Surgical $258M (+5.6%). Read full analysisCollapse analysis

Full-year TAVR growth guidance raised to 7-8% (from 6-7%), EPS raised to $2.56-$2.62.
TCT 2025 highlighted 7-year PARTNER 3 data confirming durability and 10-year Sapien outcomes, supporting long-term TAVR adoption.
TMTT momentum driven by Pascal and Evoque; Sapien M3 U.S. approval expected early 2026.

Revenue $1.5531B reported

EPS $0.67 reported

Gross margin 77.88% reported

Op margin 27.37% reported

What changed this quarter

Guidance

Company raises full-year sales growth guidance to high end of 9-10%

Guidance · revenue to $1.55B

Guidance

TAVR growth raised to 7-8%, driven by evidence and guidelines

Guidance · revenue to $1.55B

Demand

TMTT sales grew 53%, fueled by Pascal and Evoque

Management expressed strong confidence in the business, citing better-than-expected results, raising guidance, and emphasizing long-term growth drivers.

Product

Sapien M3 US approval expected by early 2026

TCT 2025 highlighted 7-year PARTNER 3 data confirming durability and 10-year Sapien outcomes, supporting long-term TAVR adoption.

Demand

Bookings & conversion

TMTT sales grew 53%, fueled by Pascal and Evoque. Management expressed strong confidence in the business, citing better-than-expected results, raising guidance, and emphasizing long-term growth drivers.

Tone · Confident

Management expressed strong confidence in the business, citing better-than-expected results, raising guidance, and emphasizing long-term growth drivers.

Forward guidance

ImprovingGuidance · revenue to $1.55B

Forward guidance
Metric	Period	Range	Midpoint	Status
EPS	FY2025	$2.56–$2.62	$2.59	RAISED
EPS	FY2025 Q4	$0.58–$0.64	$0.61	GUIDED
Revenue	FY2025 Q4	$1.51B–$1.59B	$1.55B	GUIDED

Guidance credibility

4 / 4met or beat

Guidance credibility
Issued	Metric	Target	Guide	Actual	Outcome
FY2026 Q1	EPS	FY2026 Q2	$0.70–$0.76	$0.78	Met / beat
FY2026 Q1	Revenue	FY2026 Q2	$1.66B–$1.74B	$1.741B	Met / beat
FY2025 Q4	EPS	FY2026 Q1	$0.70–$0.76	$0.78	Met / beat
FY2025 Q4	Revenue	FY2026 Q1	$1.55B–$1.63B	$1.6486B	Met / beat